INNOVIVA, INC. Purchase Obligation, to be Paid, Year One
INNOVIVA, INC. (INVA) had Purchase Obligation, to be Paid, Year One of $7.10 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInNextTwelveMonths · last filed 2024-11-06
- 2024-09-30: Purchase Obligation, to be Paid, Year One $7.10M.
- 2024-06-30: Purchase Obligation, to be Paid, Year One $6.80M.
| Period end | Purchase Obligation, to be Paid, Year One |
|---|---|
| 2024-09-30 | $7.10M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $6.80M 10-Q · filed 2024-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |